NI200900172A - Proceso abreviado de purificación para la producción de polisacaridos capsulares streptococcus pneumaniae. - Google Patents

Proceso abreviado de purificación para la producción de polisacaridos capsulares streptococcus pneumaniae.

Info

Publication number
NI200900172A
NI200900172A NI200900172A NI200900172A NI200900172A NI 200900172 A NI200900172 A NI 200900172A NI 200900172 A NI200900172 A NI 200900172A NI 200900172 A NI200900172 A NI 200900172A NI 200900172 A NI200900172 A NI 200900172A
Authority
NI
Nicaragua
Prior art keywords
capsular polysaccharides
less
production
purification process
pneumoniae
Prior art date
Application number
NI200900172A
Other languages
English (en)
Spanish (es)
Inventor
Yuan Yonghui
Ruppen Mark
Sun Wei-Qiang
Chu Ling
Simpson John
Patch James
Fink Charbonneau Pamela
K Moran Justin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200900172(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NI200900172A publication Critical patent/NI200900172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NI200900172A 2007-03-23 2009-09-21 Proceso abreviado de purificación para la producción de polisacaridos capsulares streptococcus pneumaniae. NI200900172A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89661607P 2007-03-23 2007-03-23

Publications (1)

Publication Number Publication Date
NI200900172A true NI200900172A (es) 2010-09-07

Family

ID=39712482

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900172A NI200900172A (es) 2007-03-23 2009-09-21 Proceso abreviado de purificación para la producción de polisacaridos capsulares streptococcus pneumaniae.

Country Status (29)

Country Link
US (3) US8652480B2 (enExample)
EP (3) EP2436700B8 (enExample)
JP (5) JP5688902B2 (enExample)
KR (2) KR101500771B1 (enExample)
CN (1) CN101663327B (enExample)
AU (1) AU2008231041B2 (enExample)
BR (1) BRPI0809212B8 (enExample)
CA (1) CA2681570C (enExample)
CL (2) CL2008000831A1 (enExample)
CO (1) CO6251324A2 (enExample)
CR (1) CR11041A (enExample)
DK (3) DK3406635T3 (enExample)
EC (1) ECSP099652A (enExample)
ES (3) ES2922132T3 (enExample)
GT (1) GT200900249A (enExample)
HN (1) HN2009001965A (enExample)
HU (3) HUE031567T2 (enExample)
IL (1) IL201106A (enExample)
MX (1) MX2009010221A (enExample)
MY (1) MY150927A (enExample)
NI (1) NI200900172A (enExample)
NZ (1) NZ580134A (enExample)
PL (3) PL2129693T3 (enExample)
PT (3) PT3406635T (enExample)
RU (1) RU2516340C2 (enExample)
SI (3) SI3406635T1 (enExample)
UA (1) UA99278C2 (enExample)
WO (1) WO2008118752A2 (enExample)
ZA (1) ZA200906625B (enExample)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031567T2 (hu) * 2007-03-23 2017-07-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
US11065323B2 (en) * 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
US8795689B2 (en) * 2008-12-18 2014-08-05 Wyeth Llc Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight
US20100160622A1 (en) * 2008-12-18 2010-06-24 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon dioxide
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
EP3238742A1 (en) 2009-06-22 2017-11-01 Wyeth LLC Immunogenic compositions of staphylococcus aureus antigens
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
JP5944480B2 (ja) * 2011-03-22 2016-07-05 セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド 多糖を調製するための新規な方法
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660603B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 一种快速纯化细菌荚膜多糖的方法
CN102660601B (zh) * 2012-04-17 2015-10-28 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
US9650411B2 (en) * 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
CN104781413B (zh) * 2012-09-07 2018-01-23 Sk化学公司 用于具有肺炎球菌血清型的荚膜多糖的生产方法
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
SG11201508999UA (en) 2013-07-12 2015-11-27 Emd Millipore Corp A method of determining virus removal from a sample containing a target protein using activated carbon
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
NZ759686A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HUE064837T2 (hu) * 2014-01-21 2024-05-28 Pfizer Streptococcus pneumoniae kapszuláris poliszacharidok és azok konjugátumai
HK1223273A1 (zh) 2014-01-21 2017-07-28 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
KR102149760B1 (ko) 2015-01-15 2020-08-31 화이자 인코포레이티드 폐렴구균 백신에서 사용하기 위한 면역원성 조성물
WO2016178123A1 (en) 2015-05-04 2016-11-10 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US20180223326A1 (en) * 2015-06-18 2018-08-09 The Research Foundation For Microbial Diseases Of Osaka University Method For Measuring Complement-Dependent Bactericidal Function With Respect To Pneumococci
PE20180657A1 (es) 2015-07-21 2018-04-17 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
CN105131139B (zh) * 2015-07-31 2018-02-13 兰州生物制品研究所有限责任公司 一种肺炎链球菌荚膜多糖的纯化方法
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP7001687B2 (ja) 2016-08-05 2022-02-04 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
BR112019001995A2 (pt) 2016-08-05 2019-05-07 Sanofi Pasteur, Inc. composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
EP4656208A2 (en) 2017-01-31 2025-12-03 Merck Sharp & Dohme LLC Methods for making polysaccharide-protein conjugates
MX2019009869A (es) 2017-02-24 2019-10-02 Merck Sharp & Dohme Formulaciones de vacunas de conjugado de neumococos.
AU2018225099B2 (en) 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
AU2018280272C1 (en) 2017-06-10 2021-05-06 Inventprise, Inc. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
JP7111799B2 (ja) 2017-07-05 2022-08-02 インベントプライズ リミテッド ライアビリティ カンパニー 溶菌酵素、接線流濾過、及びマルチモードクロマトグラフィを用いたワクチン生産のための多糖精製
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CN107936128B (zh) * 2017-11-22 2020-07-03 成都欧林生物科技股份有限公司 一种简便有效的细菌疫苗纯化方法
NZ765694A (en) 2017-12-06 2024-03-22 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
IL276230B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
JP7288451B2 (ja) 2018-02-05 2023-06-07 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体－タンパク質複合体組成物
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
CN112074293B (zh) 2018-04-30 2025-07-11 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EA202190168A1 (ru) 2018-07-04 2021-06-07 Ваксайт, Инк. Усовершенствования в иммуногенных конъюгатах
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
US12018134B2 (en) * 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220265803A1 (en) 2019-07-31 2022-08-25 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US12473379B2 (en) * 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
CN116075517A (zh) * 2020-06-12 2023-05-05 巴斯夫欧洲公司 改进的发酵液的脱矿化与诸如寡糖的精细化学品的纯化
JP7630603B2 (ja) 2020-08-10 2025-02-17 インベントプライズ・インコーポレイテッド 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
AU2021332183B2 (en) 2020-08-26 2025-12-18 Pfizer Inc. Group B streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
US20230383324A1 (en) 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
CN120265317A (zh) 2022-11-22 2025-07-04 辉瑞公司 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途
JP2025541706A (ja) 2022-12-01 2025-12-23 ファイザー・インク 肺炎球菌コンジュゲートワクチン製剤
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20240390471A1 (en) 2023-05-18 2024-11-28 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines
CN121263203A (zh) 2023-05-19 2026-01-02 葛兰素史克生物有限公司 诱导对呼吸道合胞病毒和肺炎链球菌感染的免疫反应的方法
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2861695D1 (en) 1977-11-07 1982-04-29 Ciba Geigy Ag Process for the manufacture of fluorinated cationic compounds and their use as surfactants
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
FR2495939B1 (fr) 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
JPS6170994A (ja) * 1984-09-14 1986-04-11 Daikin Ind Ltd 環状（１→２）−β−Ｄ−グルカンの製法
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
RU2087156C1 (ru) * 1995-06-22 1997-08-20 Леонид Николаевич Падюков Вакцина против пневмококковой инфекции
WO1999032653A1 (en) * 1997-12-23 1999-07-01 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0108079D0 (en) * 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
SI1866342T1 (sl) * 2005-04-08 2019-02-28 Wyeth Llc Ločevanje onesnaževalcev od polisaharida streptococcus pneumoniae s postopkom manipulacije pH
HUE031567T2 (hu) * 2007-03-23 2017-07-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására

Also Published As

Publication number Publication date
KR20100015765A (ko) 2010-02-12
SI2436700T1 (sl) 2018-09-28
CL2017002029A1 (es) 2018-05-18
AU2008231041A1 (en) 2008-10-02
JP2017141263A (ja) 2017-08-17
US8999697B2 (en) 2015-04-07
JP6872649B2 (ja) 2021-05-19
SI3406635T1 (sl) 2022-08-31
PT2129693T (pt) 2017-02-14
US20080286838A1 (en) 2008-11-20
IL201106A0 (en) 2010-05-17
JP2015143225A (ja) 2015-08-06
PL2436700T3 (pl) 2018-12-31
BRPI0809212B8 (pt) 2021-05-25
HUE059085T2 (hu) 2022-10-28
MY150927A (en) 2014-03-14
ECSP099652A (es) 2009-10-30
PT2436700T (pt) 2018-07-17
CR11041A (es) 2009-12-30
CN101663327B (zh) 2014-05-07
EP2129693B1 (en) 2016-12-07
CA2681570C (en) 2016-05-03
GT200900249A (es) 2010-07-28
ES2614249T3 (es) 2017-05-30
BRPI0809212B1 (pt) 2019-06-18
PT3406635T (pt) 2022-07-08
DK2436700T5 (en) 2018-09-03
RU2516340C2 (ru) 2014-05-20
CL2008000831A1 (es) 2008-07-04
AU2008231041B2 (en) 2013-03-07
RU2009135485A (ru) 2011-04-27
US8652480B2 (en) 2014-02-18
CN101663327A (zh) 2010-03-03
SI2129693T1 (sl) 2017-01-31
EP3406635A1 (en) 2018-11-28
DK3406635T3 (da) 2022-05-30
HUE031567T2 (hu) 2017-07-28
KR20150021127A (ko) 2015-02-27
JP5688902B2 (ja) 2015-03-25
US20150165017A1 (en) 2015-06-18
US9675681B2 (en) 2017-06-13
AU2008231041A8 (en) 2009-11-12
DK2436700T3 (en) 2018-08-13
JP2010521972A (ja) 2010-07-01
PL2129693T3 (pl) 2017-07-31
EP3406635B1 (en) 2022-05-11
US20140363463A1 (en) 2014-12-11
ES2677353T8 (es) 2018-09-25
PL3406635T3 (pl) 2022-08-22
WO2008118752A2 (en) 2008-10-02
HK1141815A1 (en) 2010-11-19
HN2009001965A (es) 2011-10-06
UA99278C2 (ru) 2012-08-10
MX2009010221A (es) 2009-10-19
BRPI0809212A2 (pt) 2014-09-02
KR101500771B1 (ko) 2015-03-18
IL201106A (en) 2014-04-30
JP6825950B2 (ja) 2021-02-03
EP2436700B1 (en) 2018-06-20
JP2019048844A (ja) 2019-03-28
EP2129693A2 (en) 2009-12-09
HUE039169T2 (hu) 2018-12-28
CO6251324A2 (es) 2011-02-21
CA2681570A1 (en) 2008-10-02
ZA200906625B (en) 2010-07-28
ES2922132T3 (es) 2022-09-08
EP2436700B8 (en) 2018-08-01
JP2020169160A (ja) 2020-10-15
NZ580134A (en) 2011-10-28
EP2436700A1 (en) 2012-04-04
ES2677353T3 (es) 2018-08-01
DK2129693T3 (en) 2017-02-13
WO2008118752A3 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
NI200900172A (es) Proceso abreviado de purificación para la producción de polisacaridos capsulares streptococcus pneumaniae.
BRPI0717834B8 (pt) purificação de polissacarídeos tipo 3 de streptococcus pneumoniae
WO2010135234A3 (en) Bacterial cellulose based 'green' composites
MX382322B (es) Producto fermentado que contiene un microorganismo productor de equol, por el cual se mantiene la capacidad productiva de equol, y procedimiento para la producción del mismo.
NZ600189A (en) Novel 7beta-hydroxysteroid dehydrogenases and their use
WO2009142441A3 (en) Method for producing corn gluten hydrolysate and corn gluten hydrolysate using the same
BRPI0409052A (pt) método de produção de uma poliuretano uréia, polìmero de poliuretano uréia, método de produção de fibra de spandex e spandex
BRPI1013383A8 (pt) Goma xantana, método para preparar a referida goma, composição compreendendo a mesma, alimento ou produto alimenticio, e usos de uma cepa de xanthomonas campestris e de uma goma xantana
MX338753B (es) Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
IL190088A0 (en) Protein a production and purification without using animal derived components
CN102040667B (zh) 海参多糖中蛋白的生物脱除方法
MD3437F1 (en) Process for presowing treatment of sweet pepper seeds
CN103665056A (zh) 一种氨基葡萄糖硫酸盐的制备方法
MD3582F1 (en) Process for apple-tree treatment
MD3978B1 (en) Process for dephosphatation of sewage waters
MX2009001508A (es) Un proceso novedoso para preparar ester de acido 3-amino-5-fluoro-4-dialcoxipentanoico.
Dayal et al. Synergic effects of additives on bacterial cellulose properties
RU2006114631A (ru) Способ получения l(+) молочной кислоты
BRPI0605568A (pt) composição, produto alimentìcio, leite fermentado, processo de preparação de leite fermentado e uso de bactérias streptococcus salivarius subsp salivarius
BRPI0715244B8 (pt) processo para evitar o crescimento de bactéria em um sistema de fermentação
UA83676C2 (ru) Способ получения йодида таллия особой чистоты из сырья с большим количеством примесей
TH105726B (th) กรรมวิธีสำหรับการผลิตแลคทิกแอซิดโดยการหมักของอาหารเลี้ยงเชื้อที่มีความพอเพียงในตัวที่มีพื้นฐานเป็นน้ำอ้อยดิบ
BR102015002980A2 (pt) processo para purificar polissacarídeo bacteriano
PH22007000430Y1 (en) PRODUCTION OF Schizophyllum commune MYCELIA AND SCHIZOPHYLLAN
TH98175B (th) แก้วชีวภาพจากแกลบและกระดูกสัตว์เพื่อใช้เป็นกระดูกเทียม